<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03532958</url>
  </required_header>
  <id_info>
    <org_study_id>BNZ1-CT-204</org_study_id>
    <nct_id>NCT03532958</nct_id>
  </id_info>
  <brief_title>Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of Intravenous BNZ-1 in Patients With Moderate to Severe Alopecia Areata</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioniz Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioniz Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled, multi-center, dose-ranging&#xD;
      study to characterize the efficacy and safety of BNZ-1 administered by slow IV push weekly&#xD;
      for 3 months to adults diagnosed with moderate to severe alopecia areata, defined as having a&#xD;
      &gt;50% loss of terminal hair on the scalp. The study has three periods:&#xD;
&#xD;
        -  30-Day Screening Period&#xD;
&#xD;
        -  3-Month Treatment Period&#xD;
&#xD;
        -  3-Month Follow-up Period The study will be conducted at approximately 15-20 clinical&#xD;
           sites in the United States.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline using the Severity of Alopecia Tool (SALT) score</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-Emergent Adverse Events</measure>
    <time_frame>3 months</time_frame>
    <description>Safety profile defined as incidence, severity and relationship of treatment-emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alopecia Areata Investigator Global Assessment (AA-IGA)</measure>
    <time_frame>3 &amp; 6 months</time_frame>
    <description>Hair Satisfaction Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment</measure>
    <time_frame>3 &amp; 6 months</time_frame>
    <description>Hair satisfaction scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients with SALT50</measure>
    <time_frame>3 months &amp; 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients with SALT75</measure>
    <time_frame>3 months &amp; 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients with SALT90</measure>
    <time_frame>3 months &amp; 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients with SALT100 (Disease-free)</measure>
    <time_frame>3 months &amp; 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on Alopecia Areata Symptom Impact Scale (AASIS)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Alopecia Areata</condition>
  <condition>Alopecia Totalis</condition>
  <condition>Alopecia Universalis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose BNZ-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg/kg QW</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Dose BNZ-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg/kg QW</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BNZ-1</intervention_name>
    <description>PEGylated peptide inhibitor of IL-2, IL-9, and IL-15</description>
    <arm_group_label>Low Dose BNZ-1</arm_group_label>
    <arm_group_label>Moderate Dose BNZ-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Dose volume consistent with weight-based dosing of BNZ-1</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must have a diagnosis of moderate to severe AA defined as the presence of ≥50% total&#xD;
             terminal hair loss at baseline as measured using the SALT score for &gt; 6 months, but&#xD;
             &lt;10 yrs. Includes Alopecia Totalis and Alopecia Universalis&#xD;
&#xD;
          2. Patients may be naïve to treatment or have been treated with intralesional (IL)&#xD;
             steroids or other treatments for AA, with a washout of at least 30 days or 5 times the&#xD;
             elimination half-life prior to Day 1.&#xD;
&#xD;
          3. Prior treatment with a janus kinase (JAK) inhibitor (e.g., tofacitinib, ruxolitnib) is&#xD;
             allowed, but patients considered refractory to a JAK inhibitor are excluded from this&#xD;
             trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        e subjects from this study if any of the following criteria are met:&#xD;
&#xD;
          1. Clinically relevant hepatic, neurological, pulmonary, ophthalmological, endocrine,&#xD;
             renal, or other major systemic disease making implementation of the protocol or&#xD;
             interpretation of the study results difficult, or that would put the subject at risk&#xD;
             by participating in the study in the opinion of the Investigator. Other active&#xD;
             dermatologic conditions, including but not limited to vitiligo, atopic dermatitis, or&#xD;
             non-scalp psoriasis are not exclusionary.&#xD;
&#xD;
          2. Patients with active inflammatory skin disease on the scalp, including but not limited&#xD;
             to psoriasis, seborrheic dermatitis or folliculitis, which cannot be adequately&#xD;
             controlled prior to screening.&#xD;
&#xD;
          3. Ongoing treatment with an immune system modulator or suppressant that cannot be&#xD;
             discontinued prior to screening and at least 30 days or 5-times the elimination&#xD;
             half-life prior to treatment.&#xD;
&#xD;
          4. Any ongoing topical treatment for alopecia areata&#xD;
&#xD;
          5. History of or currently active primary or secondary immunodeficiency.&#xD;
&#xD;
          6. Known active bacterial, viral, fungal, mycobacterial infection, or other infection&#xD;
             (including latent tuberculosis [TB] unless treatment is documented or atypical&#xD;
             mycobacterial disease [but excluding fungal infection of nail beds, minor upper&#xD;
             respiratory tract infection, and minor skin conditions]), or any major episode of&#xD;
             infection that required hospitalization or treatment with IV antibiotics within 60&#xD;
             days of study drug administration or oral antibiotics within 30 days prior to study&#xD;
             drug administration.&#xD;
&#xD;
          7. Received other investigational products or therapy in the 60 days prior to study drug&#xD;
             administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Eichhorn</last_name>
    <phone>949-273-6000</phone>
    <phone_ext>600</phone_ext>
    <email>David.Eichhorn@bioniz.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 10, 2018</study_first_submitted>
  <study_first_submitted_qc>May 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2018</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

